Intravenous Bone Marrow Stem Cell Grafts Preferentially Migrate to Spleen and Abrogate Chronic Inflammation in Stroke.
Bottom Line: Hematoxylin and eosin staining revealed significant 15% and 30% reductions in striatal infarct and peri-infarct area, and a trend of rescue against neuronal loss in the hippocampus.Human antigen immunostaining revealed 0.03% hBMSCs survived in spleen and only 0.0007% in brain.MSC migration to spleen, but not brain, inversely correlated with reduced infarct, peri-infarct, and inflammation. hBMSC transplantation is therapeutic in chronic stroke possibly by abrogating the inflammation-plagued secondary cell death.
Affiliation: From the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa.Show MeSH
Related in: MedlinePlus
Mentions: ANOVA revealed that there was a significant treatment effect based on fluorescent signals detected in peripheral organs and brain ex vivo (F3,11=15.25, P<0.001; Figure 2A–2C). Pairwise comparisons using post hoc tests revealed that the brain emitted a significantly lower fluorescent signal relative to the spleen of rats exposed to chronic stroke (P<0.05). The liver and lung also emitted significantly higher signals than the brain, but the spleen displayed the most prominent fluorescent signals among the peripheral organs (P<0.05).
Affiliation: From the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa.